Výsledky vyhledávání - "Flavio, Solca"

Akademický článek

Afatinib for the Treatment of Non-Small Cell Lung Cancer Harboring Uncommon EGFR Mutations: An Updated Database of 1023 Cases Brief Report

Autor: James Chih-Hsin Yang, Martin Schuler, Sanjay Popat, Satoru Miura, Keunchil Park, Antonio Passaro, Filippo De Marinis, Flavio Solca, Angela Märten, Edward S. Kim

Publikováno v: Frontiers in Oncology, Vol 12 (2022)

IntroductionPreviously, we developed a database of 693 patients with NSCLC and uncommon EGFR mutations treated with afatinib. Here, we provide an update of >1000 patients, with more data on specific mutations.MethodsPatients were identified from a pr

Externí odkaz: https://doaj.org/article/06285341cf024f7fb6cee27c5cc600a1

Zobrazit plný text záznamu

Akademický článek

Case Report: Afatinib Treatment in a Patient With NSCLC Harboring a Rare EGFR Exon 20 Mutation

Autor: Sabine Zöchbauer-Müller, Bettina Kaserer, Helmut Prosch, Agnieszka Cseh, Flavio Solca, Markus Johann Bauer, Leonhard Müllauer

Publikováno v: Frontiers in Oncology, Vol 10 (2021)

Unlike most other primary epidermal growth factor receptor (EGFR) mutations in non-small cell lung cancer (NSCLC), exon 20 insertions, comprising approximately 4% to 10% of all EGFR mutations, are generally considered to be resistant to EGFR tyrosine

Externí odkaz: https://doaj.org/article/85042a3ff8b84b48ba1aec215e208ab7

Zobrazit plný text záznamu

Akademický článek

Combined targeting EGFR and SRC as a potential novel therapeutic approach for the treatment of triple negative breast cancer

Autor: Alexandra Canonici, Alacoque L. Browne, Mohamed F. K. Ibrahim, Kevin P. Fanning, Sandra Roche, Neil T. Conlon, Fiona O’Neill, Justine Meiller, Mattia Cremona, Clare Morgan, Bryan T. Hennessy, Alex J. Eustace, Flavio Solca, Norma O’Donovan, John Crown

Publikováno v: Therapeutic Advances in Medical Oncology, Vol 12 (2020)

Background: Triple negative breast cancer (TNBC) is an aggressive subtype of breast cancer with limited therapeutic options. Epidermal growth factor receptor (EGFR) has been shown to be over-expressed in TNBC and represents a rational treatment targe

Externí odkaz: https://doaj.org/article/30ed8d6b4bc948429c56a9912d216c9d

Zobrazit plný text záznamu

Afatinib in paediatric patients with recurrent/refractory ErbB-dysregulated tumours: Results of a phase I/expansion trial

Autor: Birgit Geoerger, Lynley V. Marshall, Karsten Nysom, Guy Makin, Eric Bouffet, Anne-Sophie Defachelles, Loredana Amoroso, Isabelle Aerts, Pierre Leblond, Paulette Barahona, Kim Van-Vlerken, Eric Fu, Flavio Solca, Robert M. Lorence, David S. Ziegler

Publikováno v: Geoerger, B, Marshall, L V, Nysom, K, Makin, G, Bouffet, E, Defachelles, A, Amoroso, L, Aerts, I, Leblond, P, Barahona, P, Van-Vlerken, K, Fu, E, Solca, F, Lorence, R M & Ziegler, D S 2023, ' Afatinib in paediatric patients with recurrent/refractory ErbB-dysregulated tumours: Results of a phase I/expansion trial ', European Journal of Cancer, vol. 188, pp. 8-19 . https://doi.org/10.1016/j.ejca.2023.04.007

AimThis phase I/expansion study assessed the safety, pharmacokinetics and preliminary antitumor activity of afatinib in paediatric patients with cancer.MethodsThe dose-finding part enroled patients (2–150); HER2 membrane staining (H-score>0). The p

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::84e7ec8128779224aaf622e0bc13f9e5
https://research.manchester.ac.uk/en/publications/dd144159-5cb1-4625-acc3-ccddb47135db

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání